Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12 (16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count ≤100×109/L had a complete response, as did 3/9 with a neutrophil count 9/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.
|Number of pages||2|
|Publication status||Published - 2002|
- Myelodysplastic syndromes
ASJC Scopus subject areas